Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT06937099
- Phase
- Phase 3
- Recruitment
- Enrolling participants
- Sponsor
- Eli Lilly and Company
- Design
- Randomized
- Comparator
- Mirikizumab + Tirzepatide; Mirikizumab + Placebo
- Planned enrollment
- 290
- Endpoint
- Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction
Study ages: 18 Years to 70 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Turkey (Türkiye), United States.
Sites marked recruiting: Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Turkey (Türkiye), United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: May 2028 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1